Literature DB >> 16111541

Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.

Eric H Kraut, Donn Young, Sherif Farag, Arthur G James, Richard J Solove.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16111541     DOI： 10.1016/j.leukres.2005.03.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  4 in total

1.  Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.

Authors:  S M A Kazmi; R M Saliba; M Donato; M Wang; C Hosing; S Qureshi; P Anderlini; U Popat; R E Champlin; S A Giralt; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2010-06-28       Impact factor: 5.483

2.  The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse.

Authors:  Ombretta Annibali; Carolina Nobile; Rosa Greco; Francesco Cellini; Carlo Cosimo Quattrocchi; Maria Cristina Tirindelli; Maria Teresa Petrucci; Giuseppe Avvisati
Journal:  Int J Hematol       Date:  2009-03-26       Impact factor: 2.490

3.  Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.

Authors:  Zhengguang Li; Xingyi Li; Zhixing Cao; Youzhi Xu; Hongjun Lin; Yinglan Zhao; Yuquan Wei; Zhiyong Qian
Journal:  Oncol Rep       Date:  2012-01-12       Impact factor: 3.906

4.  VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.

Authors:  Francesca Fontana; Michael J Scott; John S Allen; Xiaoxia Yang; Grace Cui; Dipanjan Pan; Noriko Yanaba; Mark A Fiala; Julie O'Neal; Anne H Schmieder-Atteberry; Julie Ritchey; Michael Rettig; Kathleen Simons; Steven Fletcher; Ravi Vij; John F DiPersio; Gregory M Lanza
Journal:  Clin Cancer Res       Date:  2020-12-22       Impact factor: 13.801
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.